229 related articles for article (PubMed ID: 11117372)
1. Nonselective I(Kr)-blockers do not induce torsades de pointes in the anesthetized rabbit during alpha1-adrenoceptor stimulation.
Lu HR; Remeysen P; De Clerck F
J Cardiovasc Pharmacol; 2000 Dec; 36(6):728-36. PubMed ID: 11117372
[TBL] [Abstract][Full Text] [Related]
2. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
3. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
4. Importance of extracardiac alpha1-adrenoceptor stimulation in assisting dofetilide to induce torsade de pointes in rabbit hearts.
Farkas AS; Acsai K; Tóth A; Dézsi L; Orosz S; Forster T; Csanády M; Papp JG; Varró A; Farkas A
Eur J Pharmacol; 2006 May; 537(1-3):118-25. PubMed ID: 16618484
[TBL] [Abstract][Full Text] [Related]
5. Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.
Lengyel C; Varró A; Tábori K; Papp JG; Baczkó I
Br J Pharmacol; 2007 Aug; 151(7):941-51. PubMed ID: 17533421
[TBL] [Abstract][Full Text] [Related]
6. Proarrhythmic effects of intravenous quinidine, amiodarone, D-sotalol, and almokalant in the anesthetized rabbit model of torsade de pointes.
Farkas A; Leprán I; Papp JG
J Cardiovasc Pharmacol; 2002 Feb; 39(2):287-97. PubMed ID: 11791015
[TBL] [Abstract][Full Text] [Related]
7. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?
Lu HR; Hermans AN; Gallacher DJ
Br J Pharmacol; 2012 Jun; 166(4):1490-502. PubMed ID: 22300168
[TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic properties of a rapid delayed-rectifier current activator in rabbit models of acquired long QT syndrome.
Diness TG; Yeh YH; Qi XY; Chartier D; Tsuji Y; Hansen RS; Olesen SP; Grunnet M; Nattel S
Cardiovasc Res; 2008 Jul; 79(1):61-9. PubMed ID: 18367457
[TBL] [Abstract][Full Text] [Related]
9. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.
Wang WQ; Robertson C; Dhalla AK; Belardinelli L
J Pharmacol Exp Ther; 2008 Jun; 325(3):875-81. PubMed ID: 18322148
[TBL] [Abstract][Full Text] [Related]
10. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
Jacobson I; Carlsson L; Duker G
J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
[TBL] [Abstract][Full Text] [Related]
11. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model.
Lu HR; Remeysen P; Somers K; Saels A; De Clerck F
J Cardiovasc Electrophysiol; 2001 May; 12(5):538-45. PubMed ID: 11386514
[TBL] [Abstract][Full Text] [Related]
12. Effects of adenosine A1-receptor activation on torsade de pointes in rabbits.
Tan HL; Hou CJ; Sung RJ
Cardiovasc Drugs Ther; 1999 Sep; 13(5):441-7. PubMed ID: 10547225
[TBL] [Abstract][Full Text] [Related]
13. Effects of class III antiarrhythmic agents in an in vitro rabbit model of spontaneous torsades de pointe.
D'Alonzo AJ; Zhu JL; Darbenzio RB
Eur J Pharmacol; 1999 Mar; 369(1):57-64. PubMed ID: 10204682
[TBL] [Abstract][Full Text] [Related]
14. Electrophysiologic characterization of the antipsychotic drug sertindole in a rabbit heart model of torsade de pointes: low torsadogenic potential despite QT prolongation.
Eckardt L; Breithardt G; Haverkamp W
J Pharmacol Exp Ther; 2002 Jan; 300(1):64-71. PubMed ID: 11752098
[TBL] [Abstract][Full Text] [Related]
15. Antiarrhythmic effects of potassium channel openers in rhythm abnormalities related to delayed repolarization.
Carlsson L; Abrahamsson C; Drews L; Duker G
Circulation; 1992 Apr; 85(4):1491-500. PubMed ID: 1555289
[TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of ibutilide, D-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia.
Buchanan LV; Kabell G; Brunden MN; Gibson JK
J Cardiovasc Pharmacol; 1993 Oct; 22(4):540-9. PubMed ID: 7505355
[TBL] [Abstract][Full Text] [Related]
17. Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes.
Batey AJ; Coker SJ
Br J Pharmacol; 2002 Feb; 135(4):1003-12. PubMed ID: 11861329
[TBL] [Abstract][Full Text] [Related]
18. Calcium antagonist property of CPU228, a dofetilide derivative, contributes to its low incidence of torsades de pointes in rabbits.
Huang ZJ; Dai DZ; Li N; Na T; Ji M; Dai Y
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):310-7. PubMed ID: 17324143
[TBL] [Abstract][Full Text] [Related]
19. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome.
Drici MD; Clément N
Drug Saf; 2001; 24(8):575-85. PubMed ID: 11480490
[TBL] [Abstract][Full Text] [Related]
20. Uni- or bi-ventricular hypertrophy and susceptibility to drug-induced torsades de pointes.
Panyasing Y; Kijtawornrat A; Del Rio C; Carnes C; Hamlin RL
J Pharmacol Toxicol Methods; 2010; 62(2):148-56. PubMed ID: 20435152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
